BASG 奥地利人用药品质量召回·· 13 小时前精选AI 评分67
奥地利BASG通报Heparin Gilvasan 1000 IE/ml注射液因稳定性检测发现可见颗粒召回五个批次
Heparin Gilvasan 1000 IE/ml - Injektions-/Infusionslösung
AI 导读
Gilvasan Pharma GmbH于2026年10月20日通知客户，因稳定性检测发现可见颗粒，召回Heparin Gilvasan 1000 IE/ml注射液（Injektions-/Infusionslösung）五个批次。
推荐理由
材料列出五个召回批次的有效期与召回深度，可帮助药房核对库存并了解稳定性检测发现可见颗粒的范围。
正文 · 原文
Recall | Medicines | 20/10/2026
The marketing authorisation holder informed its customers on October 20, 2026, that during stability testing visible particles have been detected. For this reason, the mentioned batches are being recalled.
| Name of the medicinal product | Heparin Gilvasan 1000 IE/ml - Injektions-/Infusionslösung |
|---|---|
| Marketing authorisation number(s) | 1-12600 |
| CIP code | 3909969 |
| Marketing authorisation holder | Gilvasan Pharma GmbH |
| Batch number(s) | Batch, Expiry Date H03956, 31.03.2028 H03957, 31.03.2028 H07948, 30.04.2028 H07949, 30.04.2028 K02810, 30.09.2028 K02811, 30.09.2028 K02812, 30.09.2028 |
| Classification of the recall | 1 |
| Depth of recall | Pharmacies |
| BASG reference number | INS-640.001-5899 |
来源：BASG 奥地利人用药品质量召回 · basg.gv.at